---
title: "FDA clears Wandercraft Eve, a self-balancing walking exoskeleton"
canonical: https://smallgoodthings.org/stories/wandercraft-eve-fda-exoskeleton-2026/
sourceName: "MassDevice"
sourceUrl: "https://www.massdevice.com/wandercraft-wins-fda-clearance-for-self-balancing-exoskeleton/"
datePublished: 2026-08-12
---

# FDA clears Wandercraft Eve, a self-balancing walking exoskeleton

The FDA cleared Wandercraft’s Eve exoskeleton for personal indoor use by eligible adults with spinal cord injuries. MassDevice reported a planned 17 September 2026 US launch and a three-site clinical programme on safety and everyday tasks.

## What is the background?
Most personal exoskeletons on the US market still need crutches for balance and forward motion. Wandercraft, a Paris robotics company already known for its Atalante X rehab device, designed Eve so that eligible adults who can operate a remote can stand and walk with their hands free. MassDevice reports the cleared use is level indoor floors and immediately adjacent outdoor building areas such as patios and terraces, under a trained companion’s supervision.

That is a narrower promise than science-fiction walking, and it is the honest one. Spinal cord injury changes sitting balance, spasticity, bladder and bowel routines, and whether someone can look a visitor in the eye. Caroline Laubach, a Wandercraft test pilot quoted in the company’s release via MassDevice, described ordinary kitchen and conversation moments that seated life had made hard.

## What happened?
The US Food and Drug Administration granted clearance for Eve as a personal self-balancing exoskeleton. Wandercraft said it plans a commercial US launch on 17 September 2026 and expects Eve could become eligible for Medicare reimbursement within 60 to 90 days of that launch. Licensed clinicians will prescribe the device after a clinical assessment, an individual fitting, and training with a companion.

Training is five two-hour sessions that the company says can be completed in as little as one week. CEO Matthieu Masselin called the clearance one of the most important moments in the firm’s history.

## How did it happen?
Clearance rested on a three-site clinical trial with people who have spinal cord injuries and their companions, led by the James J. Peters VA Medical Center in the Bronx, Kessler Foundation in West Orange, New Jersey, and Walk in New York. MassDevice says the programme measured safety, function, training and readiness for personal use, including walking and activities of daily living, across a range of injury severities.

Participants and companions learned to operate Eve and met functional and usability endpoints. Some reported improvements in daily health status, psychological well-being, endurance, lower-limb spasticity and sitting balance; some also reported better sleep and bladder and bowel function. Those are participant-reported outcomes from the trial write-up, not a guarantee for every future user.

Distribution partners named in the announcement include Walk US (with a Miami site expected later in 2026), National Seating & Mobility as exclusive complex-rehab distributor across more than 180 North American locations, Good Shepherd Rehabilitation in Pennsylvania’s Lehigh Valley, and USVetServ for Department of Veterans Affairs facilities.

## Why does it matter?
Hands-free balance is the difference between needing crutches to stay upright and using your hands to open a cupboard. It does not replace a wheelchair for every surface, and it requires a trained companion. For people who meet the criteria, it is a regulated path from clinic demo to a device that can live at home, with a planned Medicare clock attached.

## What were the key results?
- FDA clearance for Eve as a personal self-balancing exoskeleton
- Intended use on level indoor surfaces and adjacent building outdoor areas
- Five two-hour training sessions with a companion before home use
- Three-site US trial covering safety, walking and daily tasks
- Planned US commercial launch on 17 September 2026
- Medicare reimbursement eligibility targeted 60 to 90 days after launch

## What happens next?
Wandercraft will start US sales through the named rehab and complex-rehab partners, including evaluation and delivery via National Seating & Mobility’s network. Walk in Miami is expected to open later in 2026. Eligibility still depends on a clinician’s assessment; people who cannot operate the remote, or who need community walking on uneven ground, are outside the cleared use.

Primary source: [MassDevice](https://www.massdevice.com/wandercraft-wins-fda-clearance-for-self-balancing-exoskeleton/)